Since EDIL3 is a regulator of EMT and both EDIL3 and EMT play important roles in the progression of cancer and acquisition of resistance to chemotherapy, we studied the expression of EDIL3 and its impact on paclitaxel resistance. Here, EDIL3 is linked to cancer.